Morepen Laboratories Limited — PPTs, 10-02-2026: Investor Presentation

**Business Performance:** Morepen Labs recorded a strong Q3 FY26 with standalone gross revenue climbing 13% year-over-year (YoY) to ₹462 Cr. This growth was predominantly driven by the Medical Devices segment, which saw a significant 44% YoY increase, reaching ₹177 Cr. In contrast, the Pharma business remained flat YoY at ₹285 Cr, as a slight 1% dip in API revenue was balanced by an 11% rise in Finished Formulations.

**Growth Drivers or Strategy:** The exceptional performance in Medical Devices, specifically Glucometers (up 40% YoY to ₹134 Cr) and BP Monitors (up 27% YoY to ₹31 Cr), underscores a clear market focus and robust demand in point-of-care diagnostics. The API segment, with key products like Atorva and Lorata+Des, continues to be a core contributor.

**Recent Developments:** The company highlights its strong leadership in glucometers, having cumulatively sold 2.33 billion test strips and 16.85 million meters year-to-date.

**Key Financial Metrics:** For Q3 FY26, standalone EBITDA improved 41% quarter-on-quarter (QoQ) to ₹46 Cr, while standalone Profit After Tax (PAT) surged 77% QoQ to ₹23 Cr.

**Management Commentary / Outlook:** No explicit management commentary or forward-looking statements were provided in the accessed investor presentation pages.